Conditions: Myeloid Leukemia, Chronic
Keywords: Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 547
Healthy volunteers: no

Brief summary:
The purpose of this clinical research study is to compare the confirmed complete cytogenetic response of dasatinib with that of imatinib within 12 months after randomization in patients with newly diagnosed chronic-phase Philadelphia positive chronic myeloid leukemia. The safety of this treatment will also be studied.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Dasatinib intervention 2: Imatinib
Intervention descriptions: intervention 1: Tablets, oral, dasatinib 50-140 mg once daily (QD) intervention 2: Tablets, oral, imatinib 200-800 mg, QD

Protocol document: